12,372 trials
Intraocular Retinoblastoma
Primary: Event-free Survival (EFS) — 0.9394; 0.9953 Estimated Probability
HBV · Chronic HBV Infection
Primary: Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 48 — 61.0; 68.4 percentage of participants
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) at 26 Weeks — -1.66; -1.45 percentage of HbA1c
Vasculitis
Primary: Time to First Relapse — NA; NA Days — p=0.884
Depressive Disorder, Major
Primary: The Number of Participants Experiencing Clinically Significant Effects — 13 participants
Pain Management, Cervical Preparation
Primary: Pain Perceived at the Time of Laminaria or Osmotic Dilator Insertion — 48.4; 56.3 units on a scale
Major Depressive Disorder
Primary: Percentage of Participants Who Meet Criteria for Re-emergence of Depressive Symptoms Estimated by Kaplan-Meier Product Limit Method (Double-blind Randomized Withdrawal…
Uncontrolled Asthma
Primary: Annualised Asthma Exacerbation Rate (AAER) up to Week 52 — 0.56; 0.54; 0.60 Events/year — p=0.5859
Idiopathic Parkinson's Disease
Primary: Unified Parkinson's Disease Rating Scale (UPDRS) Part III — -9.83; -5.91 units on a scale
Major Depressive Disorder
Primary: Change From Randomization to Week 8 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -8.47; -8.70; -7.77 units on a scale — p=0.338
Diabetes Mellitus, Type 1
Primary: Hemoglobin A1c (HbA1c) at 26 Weeks — 7.06; 7.43 percentage of HbA1c
Diabetes Mellitus, Type 1
Primary: Hemoglobin A1c (HbA1c) — 7.38; 7.61 percentage of HbA1c
Idiopathic Pulmonary Fibrosis
Primary: Relative Change From Baseline in High Resolution Computerized Tomography (HRCT) Quantitative Lung Fibrosis (QLF) Score at 6 Months — 11.407; 14.583 percent change
Ocular Hypertension · Open-angle Glaucoma
Primary: Intraocular Pressure (IOP) — 23.42; 23.37; 22.28; 21.92 mmHg — p=<0.0001
Prostatic Neoplasms
Primary: Efficacy of Leuprolide Mesylate (LMIS 50mg) — 97.0 percentage of participants